Erschienen in:
25.02.2020 | Original Article
Effect of metformin on the mortality of colorectal cancer patients with T2DM: meta-analysis of sex differences
verfasst von:
Yunzi Wang, Jingping Xiao, Yuanyu Zhao, Shijuan Du, Jiang Du
Erschienen in:
International Journal of Colorectal Disease
|
Ausgabe 5/2020
Einloggen, um Zugang zu erhalten
Abstract
Purpose
To evaluate the effect of metformin as a treatment for the mortality of colorectal cancer (CRC) patients with type 2 diabetes mellitus (T2DM).
Methods
We searched Medline, PubMed, EMBASE, Clinical
Trials.gov (
http://www.clinicaltrials.gov), and the Cochrane Collaboration Library from inception to November 2019. To analyze the relationship between metformin and the overall mortality, specific mortality, and sex differences in CRC patients with T2DM, hazard ratios (HRs) with 95% confidence intervals (CIs) were used. Egger’s test and Begg’s test were used to assess publication bias.
Results
We included 8 cohort studies in our meta-analysis. CRC patients with T2DM treated with metformin had a lower overall mortality than CRC patients with T2DM who did not receive metformin (HR = 0.80, 95% CI 0.67–0.95). There was no significant difference in CRC-specific mortality between CRC patients with T2DM who used metformin and those who did not (HR = 0.84, 95% CI 0.65–1.08). However, females had a lower CRC-specific mortality among CRC patients with T2DM than males (HR = 0.63, 95% CI 0.41–0.97).
Conclusion
Metformin reduced the overall mortality of CRC patients with T2DM. Moreover, female CRC patients with T2DM using metformin had lower CRC-specific mortality than male CRC patients with T2DM.